Jump to main content
Jump to site search


Theranostic nanoparticles escorting phosphorylated gemcitabine for advanced pancreatic cancer therapy

Abstract

Gemcitabine (GEM) has been the recommended first-line drug for patients with pancreatic ductal adenocarcinoma cancer (PDAC) since twenty years. However, GEM-based treatment has failed in many patients because of the drug resistance acquired in tumorigenesis and development. To override resistance to GEM in pancreatic cancer, we developed a visualisable, photothermally controlled, drug release nanosystem (VPNS). This nanosystem has NaLuF4:Nd@NaLuF4 nanoparticles as the luminescent core, octabutoxyphthalocyanine palladium (II) (PdPc) as the photothermal agent, and phosphorylated gemcitabine (pGEM) as the chemodrug. pGEM, one of the active forms of GEM, can circumvent the insufficient activation of GEM in cancer cell metabolism. NaLuF4:Nd@NaLuF4 nanoparticles were employed to visualise the tumor lesion in vivo by its near-infrared luminescence. The near-infrared light-triggered photothermal effect from PdPc could trigger the release of pGEM loaded in a thermally responsive ligand, and simultaneously enable photothermal cancer treatment. This work presents an effective method that suppresses the growth of tumour cells with dual-mode treatment and enables the improved treatment of orthotopic nude mice afflicted by pancreatic cancer.

Back to tab navigation

Supplementary files

Article information


Submitted
03 Jan 2020
Accepted
04 Feb 2020
First published
04 Feb 2020

J. Mater. Chem. B, 2020, Accepted Manuscript
Article type
Paper

Theranostic nanoparticles escorting phosphorylated gemcitabine for advanced pancreatic cancer therapy

Q. Wang, X. Zhu, Z. Wu, T. Sun, W. Huang, Z. Wang, X. Ding, J. Chen and F. Li, J. Mater. Chem. B, 2020, Accepted Manuscript , DOI: 10.1039/D0TB00017E

Social activity

Search articles by author

Spotlight

Advertisements